Jasper Therapeutics Inc. (JSPR) Stock Price, Quote & News

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic sp...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 549 1400

Website: jaspertx.com

Address:

2200 Bridge Pkwy, Suite 102, Redwood City, United States

BioTechChap Jun. 16 at 9:21 PM

$JSPR I struggle to understand that no BP company with strong presence in dermatology and/or immunology has sealed this no-brainer bargain. Any BD employee scouting for acquisitions who doesn’t get the ROI thesis should be dismissed instantaneously. If anything, hopefully today’s data release took away any outstanding dose dependent efficacy doubts.

1 · Reply

CannyRIFT_008 Jun. 16 at 4:16 PM

$JSPR

0 · Reply

Mario19860 Jun. 16 at 3:55 PM

$JSPR this stock is big sheet ..

0 · Reply

BioTechChap Jun. 16 at 3:28 PM

$JSPR SP is in full control of MMs. Low number of shortable shares available now (44k). This should 'recover', yet only at the grace of MMs. Load, watch and wait.

2 · Reply

yung_priest_ Jun. 16 at 3:15 PM

$JSPR 🥲

0 · Reply

elmono Jun. 16 at 3:12 PM

$JSPR yup….disappointing as always 😂😂

1 · Reply

FIREINSP Jun. 16 at 2:02 PM

$JSPR So it tanks on good news? WTF???

0 · Reply

Money_never_sleep Jun. 16 at 1:55 PM

$JSPR Big drop in good efficacy

0 · Reply

Mario19860 Jun. 16 at 1:46 PM

$JSPR again nothing....

0 · Reply

topstockalerts Jun. 16 at 1:41 PM

$JSPR strong watch at these levels🚨🚨

0 · Reply

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jun 3, 2025, 8:00 AM EDT - 13 days ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

May 14, 2025, 4:30 PM EDT - 4 weeks ago

Jasper Therapeutics to Present at Upcoming Investor Conferences

May 12, 2025, 4:05 PM EDT - 5 weeks ago

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 1, 2025, 12:45 PM EST - 3 months ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 3 months ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 27, 2025, 8:00 AM EST - 3 months ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 4:30 PM EST - 3 months ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 10, 2025, 8:00 AM EST - 4 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 4, 2025, 4:30 PM EST - 4 months ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 5 months ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 6, 2025, 8:00 AM EST - 5 months ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Dec 2, 2024, 4:30 PM EST - 7 months ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Nov 18, 2024, 10:09 AM EST - 7 months ago

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 13, 2024, 4:30 PM EST - 7 months ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 7, 2024, 7:30 AM EST - 7 months ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 24, 2024, 8:00 AM EDT - 8 months ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 14, 2024, 9:22 AM EDT - 8 months ago

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

Oct 14, 2024, 7:00 AM EDT - 8 months ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Sep 10, 2024, 7:30 AM EDT - 9 months ago

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Sep 4, 2024, 4:30 PM EDT - 10 months ago

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

Aug 13, 2024, 7:00 AM EDT - 10 months ago

Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Jun 19, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

Jun 17, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit

Jun 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress

May 30, 2024, 6:05 PM EDT - 1 year ago

Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

May 29, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments

May 13, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Briquilimab Development Program in Asthma

May 7, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at Upcoming Investor Conferences in May

Apr 2, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 21, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

Mar 15, 2024, 8:00 AM EDT - 1 year ago

New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

Mar 4, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments

Feb 26, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference

Feb 23, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 7, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference

Feb 6, 2024, 8:59 AM EST - 1 year ago

Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock

Feb 5, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 2, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 5, 2024, 8:30 AM EST - 1 year ago

Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

Jan 2, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics, Inc. Announces Reverse Stock Split

Dec 10, 2023, 11:00 AM EST - 1 year ago

Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023

Nov 30, 2023, 8:00 AM EST - 1 year ago

Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

Nov 9, 2023, 8:00 AM EST - 1 year ago

Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences

Nov 2, 2023, 9:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023

Nov 1, 2023, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

Oct 9, 2023, 8:30 AM EDT - 1 year ago

Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023

BioTechChap Jun. 16 at 9:21 PM

1 · Reply

CannyRIFT_008 Jun. 16 at 4:16 PM

$JSPR

0 · Reply

Mario19860 Jun. 16 at 3:55 PM

$JSPR this stock is big sheet ..

0 · Reply

BioTechChap Jun. 16 at 3:28 PM

$JSPR SP is in full control of MMs. Low number of shortable shares available now (44k). This should 'recover', yet only at the grace of MMs. Load, watch and wait.

2 · Reply

yung_priest_ Jun. 16 at 3:15 PM

$JSPR 🥲

0 · Reply

elmono Jun. 16 at 3:12 PM

$JSPR yup….disappointing as always 😂😂

1 · Reply

FIREINSP Jun. 16 at 2:02 PM

$JSPR So it tanks on good news? WTF???

0 · Reply

Money_never_sleep Jun. 16 at 1:55 PM

$JSPR Big drop in good efficacy

0 · Reply

Mario19860 Jun. 16 at 1:46 PM

$JSPR again nothing....

0 · Reply

topstockalerts Jun. 16 at 1:41 PM

$JSPR strong watch at these levels🚨🚨

0 · Reply

elmono Jun. 16 at 1:14 PM

$JSPR already selling off again on mini pump. Feels equity raise around the corner. Too bad. Low quality business acumen 🤷‍♂️

0 · Reply

DrKunta Jun. 16 at 1:01 PM

$JSPR they seem to speak more of a 240mg loading followed by a 180mg q8w. Suggests that the 120mg/180mg weard response dose is more of an accident than a reality. 16wk 180mg every 8wks data in the Beacon poster shows the 180mg response goes under the 120mg even if the 120mg goes deeper in terms of UAS7. In short, the story about miadiagnosis seems to hold. We will now for sure in July/August from what they shared today. Still crazy to see the 15x difference in valuation with CLDX given the better data.

0 · Reply

BioTechChap Jun. 16 at 12:51 PM

$JSPR Solid conference call. 1 analyst Q on grade 2 neutropenia, answer in line with information shared pro-actively. Quite a few analysts asking Qs about dosing schedule (240/360mg, loading dose, biomarker-led dosing, QW8 or QW12 etc.) clearly anticipating upcoming readout of BEACON. The one thing that stood out to me is that company is even considering 360mg loading dose (across indications), apparently not holding back on safety consideration. This implies a bullish sentiment running up to BEACON readout.

0 · Reply

topstockalerts Jun. 16 at 12:36 PM

$JSPR strong watch for today..👀..👀..

0 · Reply

topstockalerts Jun. 16 at 12:09 PM

$JSPR where’s she going next??💸💸

1 · Reply